Injection site reactions are the most common side effect of Emgality. The most frequent injection site reaction is pain. But there are steps you can take to help prevent or reduce pain from Emgality ...
Emgality’s most common side effect is a reaction at the injection site. This can cause itching, pain, skin discoloration, or swelling. Other possible side effects include high blood pressure and ...
Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...
INDIANAPOLIS, June 15, 2021 /PRNewswire/ -- To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) compared to ...
INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 ...
INDIANAPOLIS, May 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of results from pooled subgroup analyses of efficacy data from the Phase 3 ...
The CHALLENGE-MIG study demonstrates Lilly's commitment to migraine research and results underscore that people living with episodic migraine deserve broad access to effective treatments "These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results